To: Oncologic Drugs Advisory Committee Members and Guests
From: Richard Pazdur, M.D.
Director, Division of Oncology Drug Products, CDER, FDA
This memo outlines the purpose of the December meeting of ODAC and describes the contents of this briefing package.
The Food and Drug Administration is undertaking a project to evaluate potential endpoints for cancer drug approval. Endpoints will be examined for the most common cancers, such as lung cancer, colon cancer, etc. For each cancer, FDA will hold public workshops to identify important issues, and these issues will be discussed in meetings of the Oncologic Drugs Advisory Committee (ODAC). Subsequently, guidance documents will be published describing FDA's current thinking on endpoints for cancer drug approval.
the morning and afternoon sessions of the December 16th meeting will
address cancer endpoints. In the morning, general cancer endpoint issues will be discussed,
especially the role of time to progression. The afternoon session will focus on endpoints
in lung cancer. The afternoon session
will include presentations from partipants in the
lung cancer endpoint workshop held
Documents in this background package include:
General background documents:
TAB 1 Endpoints that have supported cancer drug approval (JCO article)
TAB 2 FDA efficacy guidance
TAB 3 Cancer supplemental applications guidance
TAB 4 Executive summary of workshop discussion
TAB 5 1990 FDA guideline on drug approval in lung cancer
Please also refer to the FDA endpoints web page for additional background documents and slides from the April lung cancer workshop presentations